Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00071851 · ClinicalTrials.gov registry record · Phase 1

Safety of and Immune Response to an HIV-1 DNA Vaccine (VRC HIVDNA009-00-VP) in HIV Uninfected Adults

A Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
Phase 1
Development phase
180
Enrollment target
14
Study locations

NCT00071851 is a Phase 1 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 180 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (60% lower). The trial reports 14 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00071851, a Phase 1 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
Phase 1
Development phase
180 participants
Enrollment target
14
Study locations

Study Summary

The purpose of this study is to test the safety of and immune response to an HIV-1 vaccine, VRC-HIVDNA009-00-VP, in HIV uninfected participants. Two different doses of the vaccine will be tested.

Conditions Studied

HIV Infections

Interventions

  • BIOLOGICAL VRC-HIVDNA009-00-VP

Study Locations (14)

New York

  • NY Blood Ctr./Union Square CRS - New York
  • HIV Prevention & Treatment CRS - New York
  • Univ. of Rochester HVTN CRS - Rochester
  • NY Blood Ctr./Bronx CRS - The Bronx

Maryland

  • Project Brave HIV Vaccine CRS - Baltimore
  • Johns Hopkins Bloomberg School of Public Health,Ctr for Immunization Research,Project SAVE-Baltimore - Baltimore

Massachusetts

  • Brigham and Women's Hosp. CRS - Boston
  • Fenway Community Health Clinical Research Site (FCHCRS) - Boston

Alabama

  • Alabama Vaccine CRS - Birmingham

California

  • San Francisco Vaccine and Prevention CRS - San Francisco

Missouri

  • Saint Louis Univ. School of Medicine, HVTU - St Louis

Rhode Island

  • Miriam Hospital's HVTU - Providence

Tennessee

  • Vanderbilt Vaccine CRS - Nashville

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2003-12
Est. Completion 2005-10
Phase Phase 1

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00071851

The ClinicalTrials.gov registry entry for NCT00071851 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (60% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which VRC-HIVDNA009-00-VP is the first listed.

NCT00071851 reports 14 study locations spanning 9 distinct geographic areas - top geographies include New York, Maryland, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00071851 about?

NCT00071851 is a clinical study titled "Safety of and Immune Response to an HIV-1 DNA Vaccine (VRC HIVDNA009-00-VP) in HIV Uninfected Adults". The purpose of this study is to test the safety of and immune response to an HIV-1 vaccine, VRC-HIVDNA009-00-VP, in HIV uninfected participants. Two different doses of the vaccine will be tested.

What is the current status of trial NCT00071851?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 180 participants. The study started on 2003-12. Estimated completion is 2005-10.

What conditions does trial NCT00071851 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00071851?

The interventions under investigation include: VRC-HIVDNA009-00-VP (BIOLOGICAL).

Who is sponsoring clinical trial NCT00071851?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00071851 being conducted?

This trial has 14 study locations across Alabama, California, Maryland, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infections

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.